AGP Executive Report
Last update: 6 hours agoIllinois Access: The state added sickle cell disease and polyendocrine metabolic ovarian syndrome with chronic pain to its medical cannabis eligibility list, bringing the total to 58 conditions. Sleep Research: A long-term study linked cannabis use to poorer sleep measured by wearable monitors, though users didn’t report noticing the difference. Cannabinoid Medicine: New York approved a trial of THC oral solution for sciatica-related chronic pain, while FDA cleared a pathway for conditional approval of a cannabinoid drug for canine bone-cancer pain. University of Regina researchers are also studying CBD as a possible concussion treatment. Hemp Policy: The hemp THC industry is pushing Congress to preserve legal products as a federal ban looms, amid growing uncertainty for businesses.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.